Robert W. Baird reissued their hold rating on shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) in a research note published on Tuesday morning. The firm currently has a $7.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $9.00.

Several other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Amicus Therapeutics from a hold rating to a sell rating in a report on Thursday, August 11th. Chardan Capital set a $15.00 target price on shares of Amicus Therapeutics and gave the company a buy rating in a report on Thursday, August 11th. Cowen and Company reiterated an outperform rating and issued a $15.00 target price on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Finally, Leerink Swann restated a buy rating and issued a $17.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $11.31.

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 6.51 on Tuesday. The stock’s market cap is $926.54 million. Amicus Therapeutics has a one year low of $4.98 and a one year high of $11.02. The stock’s 50 day moving average price is $7.82 and its 200 day moving average price is $6.97.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analyst estimates of $1.71 million. Analysts forecast that Amicus Therapeutics will post ($1.38) earnings per share for the current year.

WARNING: “Amicus Therapeutics Inc. (FOLD) Given “Hold” Rating at Robert W. Baird” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of international copyright and trademark laws. The legal version of this piece can be viewed at http://www.dailypolitical.com/2016/11/30/amicus-therapeutics-inc-fold-given-hold-rating-at-robert-w-baird.html.

In related news, SVP Daphne Quimi sold 8,546 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $8.00, for a total value of $68,368.00. Following the completion of the sale, the senior vice president now directly owns 24,189 shares of the company’s stock, valued at $193,512. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total transaction of $175,000.00. Following the completion of the sale, the insider now directly owns 583,453 shares of the company’s stock, valued at $4,084,171. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

A number of large investors have recently made changes to their positions in FOLD. Dynamic Technology Lab Private Ltd bought a new stake in shares of Amicus Therapeutics during the second quarter worth $108,000. Principal Financial Group Inc. boosted its stake in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,122 shares during the period. BlackRock Inc. boosted its stake in shares of Amicus Therapeutics by 224.8% in the second quarter. BlackRock Inc. now owns 26,443 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 18,301 shares during the period. SG Americas Securities LLC bought a new stake in shares of Amicus Therapeutics during the third quarter worth $151,000. Finally, State Board of Administration of Florida Retirement System boosted its stake in shares of Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.